Predictors of T Cell Expansion and Clinical Responses Following B-Cell Maturation Antigen-Specific Chimeric Antigen Receptor T Cell Therapy (CART-BCMA) for Relapsed/Refractory Multiple Myeloma (MM)
Blood (2018) 132 (Supplement 1): 1974.
Currently there are no citedby results. Try again later.
